The 4-day program combined a broad range of topics from the rapidly evolving field of haematology. Updates on the diagnosis and management of patients with haematological disorders, as well as presentations on the cutting edge of basic, translational and clinical research were presented in over 400 sessions of invited presentations, abstract presentations and sponsored sessions from EHA’s industry partners. Original unpublished data formed the core of the program, with some large clinical trials pushing the evidence-base of primary clinical relevance, with likely practice-changing outcomes.
Two topics-in-focus were highlighted as well at this meeting, because of their impending high-impact in this field: advances in haemoglobinopathies and immunotherapy. Within the area of haemoglobinopathies, several promising developments in sickle cell disease management will bring changes to daily practice in the near future. For immunotherapy, CAR T-cell therapy has been marked by particularly rapid success in the clinic, with steadily better results, as we start to understand the safety profile and underlying biology modulating response. This year was the start of implementing such focussed programs aimed at raising awareness, providing education, furthering research, and building a network of experts with the ultimate goal to improve patient care. This Conference Report aims to bring the conference to the physician, by summarising the main points of interest in a peer-reviewed and balanced manner.
Enjoy the read!
Medicom Medical Publishers
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Residual disease in AML patients prior to stem cell transplant increases relapse risk Next Article
CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma »
« Residual disease in AML patients prior to stem cell transplant increases relapse risk Next Article
CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma »
Table of Contents: EHA 2019
Featured articles
Editor Biography
Interview with EHA President Prof. Pieter Sonneveld
Myeloid Malignancies
Residual disease in AML patients prior to stem cell transplant increases relapse risk
Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML
Initial data on AMV564 in patients with relapsed/refractory AML
Overcoming the “don’t eat me” signal in AML and MDS
Asciminib plus imatinib in patients with heavily pre-treated chronic myeloid leukaemia
Guadecitabine vs treatment of choice in AML
Lymphoid Malignancies
Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL
CAR-T cell therapy in ALL as breakthrough advance
Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma
Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma
Obinutuzumab/polatuzumab in follicular lymphoma
Exciting survival data for ibrutinib vs placebo in treatment-naĂŻve, early-stage CLL
ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL
Venetoclax-obinutuzumab combination elicits high response rates in CLL
Myeloma
CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma
Chimeric antigen receptor T cell therapy in multiple myeloma
Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM
Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM
Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis
Venetoclax for multiple myeloma: effective but some safety concerns
Benign Haematology
New sickle cell drug voxelotor boosts levels of haemoglobin
Positive initial data evaluating the safety and efficacy of IMR-687 for treatment of sickle cell disease
Haematopoietic stem cell transplantation improves stroke risk in children with sickle cell anaemia
Early trial data shows positive results for treating anaemia in patients with end-stage renal failure
Bench-to-Bedside
Transformation of foetal haematopoietic stem and progenitor cells in the background of trisomy 21
Treating thalassemia twice, in mice
Haematopoietic stem cells can sense tissue damage in the gut
Promising news for gene therapy for sickle cell disease
Related Articles
August 9, 2019
Obinutuzumab/polatuzumab in follicular lymphoma
August 9, 2019
Treating thalassemia twice, in mice
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy